15
Phase 2–4 trials
Two KRAS G12C inhibitors in solid tumours
Adagrasib vs sotorasib: trial pipelines compared
A side-by-side view of the adagrasib and sotorasib clinical trial pipelines, built from live ClinicalTrials.gov data and refreshed daily. ClinicalTrials.gov lists 15 phase 2–4 trials for adagrasib and 16+ for sotorasib. Add up to three more drugs to widen the comparison.
adagrasib (15) vs sotorasib (16)28 active2019–2032
adagrasibsotorasib
'19
'21
'23
'25
'27
'29
'31
adagrasib
Genetic Testing in Guiding Treatment for Patients With Brain MetastasesP2
Phase 2 Trial of Adagrasib Monotherapy and in Combination With Pembrolizumab and a Phase 3 Trial of Adagrasib in Combination in Patients With a KRAS G12C Mutation KRYSTAL-7P2
KRYSTAL-12P3
Phase 3 Study of MRTX849 With Cetuximab vs Chemotherapy in Patients With Advanced Colorectal Cancer With KRAS G12C Mutation (KRYSTAL-10)P3
Combination Therapies With Adagrasib in Patients With Advanced NSCLC With KRAS G12C MutationP2
Neo-KanP2
ADEPPTP2
A Phase 2 Basket Trial in Which Patients With Advanced Solid Tumors Carrying the KRAS G12C mUtation Receive Treatment With a Combination of Sotorasib and PanitumumabP2
Trial of Two Adagrasib Dosing Regimens in NSCLC With KRAS G12C Mutation (KRYSTAL 21)P2
Adagrasib + SRS for Patients With Metastatic KRAS G12C-mutated NSCLC With Untreated Brain MetastasesP2
Krascendo 1P3
A Study of Adagrasib Plus Pembrolizumab Plus Chemotherapy vs. Placebo Plus Pembrolizumab Plus Chemotherapy in Participants With Previously Untreated Non-squamous Non-small Cell Lung Cancer With KRAS G12C Mutation (KRYSTAL-4)P3
Immunotherapy Biomarkers to Predict First-line PD(L)1-based Immunotherapy Response and Selection of Second-line Treatment in Stage IIIB-IV Non-small Cell Lung Cancer, IMMUNO-BIOMAP TrialP2
A Solid Tumor Study for Long Term Treatment of Cancer Patients Who Participated in Adagrasib StudiesP2
CIMAvax-EGF With KRAS G12C Inhibitor for the Treatment of Advanced, KRAS G12C Mutated Non Small Cell Lung CancerP2
sotorasib
Testing the Use of Targeted Treatment (AMG 510) for KRAS G12C Mutated Advanced Non-squamous Non-small Cell Lung Cancer (A Lung-MAP Treatment Trial)P2
Combination Study of RMC-4630 and Sotorasib for NSCLC Subjects With KRASG12C Mutation After Failure of Prior Standard TherapiesP2
CodeBreaK201P2
CodeBreak300P3
SOLUCOMP2
CODEBREAK-IGRP2
Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening TrialP2
A Phase 2 Basket Trial in Which Patients With Advanced Solid Tumors Carrying the KRAS G12C mUtation Receive Treatment With a Combination of Sotorasib and PanitumumabP2
ROSIEP4
A Study Evaluating Sotorasib Platinum Doublet Combination Versus Pembrolizumab Platinum Doublet Combination as a Front-Line Therapy in Participants With Stage IV or Advanced Stage IIIB/C Nonsquamous Non-Small Cell Lung Cancers (CodeBreaK 202)P3
CodeBreaK 301P3
Testing the Use of AMG 510 (Sotorasib) and Panitumumab as a Targeted Treatment for KRAS G12C Mutant Solid Tumor Cancers (A ComboMATCH Treatment Trial)P2
A Study of Sotorasib in People With Non-Small Cell Lung CancerP2
Krascendo 1P3
COLOSOTOP2
CIMAvax-EGF With KRAS G12C Inhibitor for the Treatment of Advanced, KRAS G12C Mutated Non Small Cell Lung CancerP2
Upcoming readouts
18 ahead · 2 drugs
Select a trial to load its full ClinicalTrials.gov record.
Head to head
Registered phase 2–4 trial activity for each drug, computed from live ClinicalTrials.gov data.
adagrasib (Krazati)KRAS inhibitors
4
Phase 3 trials
5
Actively recruiting
Sept 2029
Next phase 3 readout
sotorasib (Lumakras)KRAS inhibitors
16+
Major trials tracked
4
Phase 3 trials
5
Actively recruiting
Jun 2027
Next phase 3 readout
Key trials across both drugs
Top 16 registered phase 2–4 trials across adagrasib and sotorasib, ordered by phase and status. Each links to its full ClinicalTrials.gov record.
| Drug | Trial | Title | Phase | Status | Primary completion |
|---|---|---|---|---|---|
| sotorasib | NCT06314763 | ROSIE: Rivaroxaban Sotorasib Interaction Study | Phase 4 | Completed | Mar 2024 |
| sotorasib | NCT05920356 | A Study Evaluating Sotorasib Platinum Doublet Combination Versus Pembrolizumab Platinum Doublet … | Phase 3 | Recruiting | Jun 2027 |
| sotorasib | NCT06252649 | CodeBreaK 301: Study of Sotorasib, Panitumumab and FOLFIRI Versus FOLFIRI With or Without Bevacizumab-awwb in T… | Phase 3 | Recruiting | Sept 2028 |
| adagrasib | NCT06875310 | A Study of Adagrasib Plus Pembrolizumab Plus Chemotherapy vs. Placebo Plus Pembrolizumab Plus Ch… | Phase 3 | Recruiting | Sept 2029 |
| adagrasib | NCT04685135 | KRYSTAL-12: Phase 3 Study of MRTX849 (Adagrasib) vs Docetaxel in Patients With Advanced Non-Small Cell Lung … | Phase 3 | Active, not recruiting | Dec 2023 |
| adagrasib | NCT04793958 | Phase 3 Study of MRTX849 With Cetuximab vs Chemotherapy in Patients With Advanced Colorectal Can… | Phase 3 | Active, not recruiting | Jan 2026 |
| adagrasib | NCT06497556 | Krascendo 1: A Study Evaluating the Efficacy and Safety of Divarasib Versus Sotorasib or Adagrasib in Partici… | Phase 3 | Active, not recruiting | May 2026 |
| sotorasib | NCT06497556 | Krascendo 1: A Study Evaluating the Efficacy and Safety of Divarasib Versus Sotorasib or Adagrasib in Partici… | Phase 3 | Active, not recruiting | May 2026 |
| sotorasib | NCT05198934 | CodeBreak300: Sotorasib and Panitumumab Versus Investigator's Choice for Participants With Kirsten Rat Sarcoma… | Phase 3 | Completed | Jul 2025 |
| sotorasib | NCT06582771 | A Study of Sotorasib in People With Non-Small Cell Lung Cancer | Phase 2 | Recruiting | Aug 2026 |
| adagrasib | NCT06248606 | Adagrasib + SRS for Patients With Metastatic KRAS G12C-mutated NSCLC With Untreated Brain Metast… | Phase 2 | Recruiting | Feb 2027 |
| sotorasib | NCT05631249 | CODEBREAK-IGR: Sotorasib in Previously Treated Locally Advanced or Metastatic NSCLC Subjects With Mutated KRAS … | Phase 2 | Recruiting | Dec 2027 |
| adagrasib | NCT07415031 | A Solid Tumor Study for Long Term Treatment of Cancer Patients Who Participated in Adagrasib Stu… | Phase 2 | Recruiting | Feb 2028 |
| adagrasib | NCT07288034 | Immunotherapy Biomarkers to Predict First-line PD(L)1-based Immunotherapy Response and Selection… | Phase 2 | Recruiting | Oct 2028 |
| adagrasib | NCT04613596 | Phase 2 Trial of Adagrasib Monotherapy and in Combination With Pembrolizumab and a Phase 3 Trial… | Phase 2 | Recruiting | Oct 2028 |
| sotorasib | NCT05564377 | Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advan… | Phase 2 | Recruiting | Jul 2030 |
Individual pipelines and other comparisons
FAQ
- How do the adagrasib and sotorasib clinical pipelines compare?
- ClinicalTrials.gov currently lists 15 phase 2–4 trials for adagrasib and 16+ for sotorasib. The timeline above plots both side by side and refreshes daily.
- Where does this data come from?
- All trial data is sourced from ClinicalTrials.gov (CTGov) and refreshed on this page daily. ComplyRx does not add efficacy or superiority claims; the comparison shows registered trial activity only.
- Can I add more drugs to the comparison?
- Yes. The tool above compares up to five drugs on one timeline, with PNG and PDF export. Add any competitor in the search box.